Concord Biotech Limited’s Board of Directors convened on October 27, 2026, to approve the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The board also fixed November 04, 2026, as the record date for identifying shareholders eligible for the previously announced bonus equity shares. The committees of the board were also reconstituted.
Financial Results and Bonus Share Approval
Concord Biotech Limited announced that its Board of Directors, following a meeting on October 27, 2026, has approved the unaudited standalone and consolidated financial results for the second quarter and the six-month period ended September 30, 2026. These results were reviewed and recommended by the Audit Committee. The company also provided the Limited Review Reports issued by its statutory auditors, M/s. BSR & Co. LLP.
Record Date for Bonus Issue Fixed
Further to a prior intimation dated September 23, 2026, the Board has set Wednesday, November 04, 2026, as the record date for determining the shareholders who will receive bonus equity shares. The company will issue a separate disclosure to the stock exchanges regarding this allocation.
Committee Reconstitution
In compliance with SEBI regulations, the Board of Directors also reconstituted key committees, including the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee. The updated composition of these committees is detailed in Annexure A.
Meeting Details
The Board Meeting commenced at 03:30 PM and concluded at 04:45 PM on October 27, 2026.
Source: BSE
